AgriMetis, LLC is pleased to announce the opening of its new laboratory in Gaithersburg, Maryland. The new laboratory is located at 401 Professional Drive, which is in the heart of the Maryland Biotech region along the I-270 corridor.
Is your biohealth company located in Maryland, DC or Virginia? Are you thinking of applying for a biohealth related SBIR grant? Does your technology qualify? Are you eligible? Should you apply to NIH? NSF? to other organizations?
Sign up now to learn more from one of BHI’s SBIR consultants. Office hours are scheduled next in Montgomery County August 8th and 15th. (There is no fee for this service. Depending upon your technology and stage in the business cycle, BHI may also prepay for experts to help you improve your SBIR and other non-dilutive funding applications. For more information, click here.)
Rachel King, co-Founder and Chief Executive Officer of GlycoMimetics, Inc., testified today on behalf of the Biotechnology Innovation Organization (BIO) before the Joint Economic Committee. King discussed the need to build on the success of the JOBS Act, FDASIA’s “breakthrough therapies” designation, as well as policies that provide tax relief and strengthen patent protections.
Don’t miss the opportunity to participate in this fun networking event with colleagues throughout Maryland, DC and Virginia at the 5th Annual BioHealth Capital Region BioBowl. Co-hosted by MedImmune and BioHealth Innovation, this unique event is open to biohealth companies from throughout the region who value team building with their work colleagues and the opportunity to meet others at nearby companies. You do not have to be a probowler to participate! Prizes include the coveted BHCR Bowling Trophy and a Rubber Chicken Award. The entire BowlMor facility in Gaithersburg will be filled with BioHealth bowlers from 4-6:30 p.m. on October 11th. Come join us! Food and beverages are complimentary but pre-registration is required. For more information, email BHI.
Attention NHLBI SBIR/STTR Phase II companies, The NIH Commercialization Accelerator Program (CAP) is now accepting applications
The deadline for submitting an application for NIH CAP is August 16, 2018 by 11:59 pm PDT. Up to eighty (80) companies will be selected to participate in this year’s NIH CAP in early September 2018.
The CAP program is designed to help recent Phase II awardees with individualized assistance in Market & Customer Discovery, Development, Business Strategy and Outcomes and Regulatory & Reimbursement Strategies to help you transition your SBIR-STTR developed product into the marketplace.
With a dozen approvals for biosimilars under its belt already, the Food and Drug Administration has started a new effort to accelerate the development and adoption of the drugs.
The House and Senate have agreed to the John S. McCain National Defense Authorization Act for FY 2019. As anticipated, the legislation addresses many small business and innovation policies. Changes relevant to tech-based economic development affect SBIR, advanced manufacturing, and partnerships with defense labs.
GlaxoSmithKline has made a $300 million equity investment in 23andMe as part of a deal that pulls it close to the consumer genetics pioneer. The partners are contributing preclinical programs to a 50-50 collaboration that will use 23andMe’s genotypic and phenotypic data to accelerate progress.
RESI invites global early stage companies across biotech, medtech, diagnostics & digital health to apply to their next Innovation Challenge.
Gain excellent visibility among investors and strategic partners.
Top 30 selected companies will showcase their technology in a poster format in the exhibit hall at the RESI Conference, September 6thin Boston. Winners will be announced and awarded during the cocktail reception, and all finalists will be featured in the program guide, on the RESI website and announced in LSN’s newsletter to a readership of 20,000+.
Where: Inova Center for Personalized Health 3225 Gallows Rd Fairfax, Virginia 22037 United States
Women of the Virginia bioscience community from across the state will lead this full day event offering examples of working together to build a stronger bioscience industry, stronger companies and institutions, stronger teams and networks, and stronger individuals.
Due to company graduations, co-working and individual office space is becoming available at the Montgomery County innovation centers located in Rockville and Germantown. Each location offers shared meeting and kitchenette/lunch room space, and affordable, flexible lease terms. Tenants in these facilities also have access to BHI Entrepreneurs-in-Residence analysts, and other professional staff for additional support. For more information, contact BHI.
MACH37, the premier market-centric cyber accelerator in the United States, today announced they will begin accepting applications for the Fall 2018 Cohort, which will commence on Sept. 24. Designed to facilitate the development of the next generation of cyber companies, MACH37’s unique program places heavy emphasis on the validation of complex cyber problems, the development of unique solutions, and the cultivation of relationships that produce market traction and investment capital.
An incubator space is coming to Cherry Hill Mall — a change that points to the broader trend of shopping centers rebranding as destinations to do more than just buy clothes.
Glaxo Smith Kline (GSK) with facilities in Collegeville and Valley Forge, reported first half 2018 results, increased their guidance for the remainder of the year and announced a major restructuring program expected to deliver annual cost savings of £400 million by 2021.
